I've never, in three years, seen a compelling argument that substantiates why RAC investors are crazy, or that the IP is a bad bet or anything else related to to the strategy the team are employing. Nothing, outside of standard clinical or investment risks inherent to all biotechs, anyway.
I would love to hear those arguments rationalised. Most of them come down to "we don't like how visible DT is on social media and in forums - it must be a pump and dump."
I strongly, strongly believe the science is water-tight and the risk is very low - in line with the standard investment risks, or less.
I've never, in three years, seen a compelling argument that...
-
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |